One of the highlights was my conversation with Dr. David Libon, PhD, ABN, FAPCN, a professor at Rowan University's New Jersey Institute of Successful Aging and advisor at Linus Health. We discussed the groundbreaking new medicines for Alzheimer’s and what it takes to get them through regulatory approval—a monumental achievement for patients and caregivers. But that’s just the start.
We also dove into:
✨ The complexities of Alzheimer medication titration.
✨ Who should be eligible for these therapies?
✨ How these advancements could transform care.
Don’t miss this discussion about the future of brain health. Stay tuned!